Investor's Business Daily on MSN6h
Novo Nordisk Finds A New Way To Rival Eli Lilly. But Shares Tumble.
Novo Nordisk stock dropped Monday after the drugmaker licensed a Chinese competitor's diabetes and weight-loss drug for up to $2 billion.Novo will pay The United Laboratories International $200 ...
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped
In contrast, Eli Lilly (NYSE: LLY) and Hims & Hers Health (NYSE: HIMS) both jumped on today's news. They rose 2.7% and 7%, ...
BioPharma Dive10h
Novo adds to obesity drug pipeline via $200M deal with China-based biotech
The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.
Was Jim Cramer Right About Eli Lilly and Company (LLY)?
We recently published a list of Was Jim Cramer Right About These 23 Stocks? In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim ...
Novo bets on 'triple G' obesity drug in up to $2 billion deal with Chinese biotech
Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G ...
BioSpace13h
Novo Challenges Lilly With up to $2B Bet for Triple-G Obesity Drug From Chinese Biotech
Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...
The Manila Times14h
Sesame, America's Low-Cost Leader in Healthcare, Streamlines Access for Eligible Patients to Lilly's Obesity Medicine Zepbound
Streamlined access to authentic, FDA-approved, rigorously-tested Zepbound comes from Sesame's direct integration with Gifthealth. Zepbound is the first and only FDA-approved dual glucagon-like peptide ...